Esperion Therapeutics Inc. on Monday reported positive results in a late-stage trial of a treatment for patients with atherosclerotic cardiovascular disease (ASCVD). The company said the Phase 3 trial sought to evaluate the efficacy and safety of the bempedoic acid 180 mg / ezetimibe 10 mg combination pill compared to bempedoic acid, ezetimibe or placebo in patients treated with maximally tolerated statins. The study involving 382 high-risk patients met its key endpoints, including lowering LDL-C, or "bad" cholesterol, by 35%. It also achieved a 34% reduction in high-sensitivity C-reactive protein (hsCRP), which the company said is an important marker of the underlying inflammation associated with cardiovascular disease. "With the combo pill we are confident physicians will have the treatment option they need to help the more than 12 million Americans with high LDL-C already taking maximally tolerated statin therapy, conveniently and cost-effectively achieve lower LDL-C levels," Tim Mayleben, Esperion chief executive said in a statement. Shares were halted for the news premarket, but have fallen 25.5% in 2018, while the S&P 500 has gained 7.5%.
Have breaking news sent to your inbox. Subscribe to MarketWatch's free Bulletin emails.